Elevated Insights

From gene editing to biomanufacturing, learn more about the cell and gene therapy industry from our team of industry-leading experts

Featured Insights

// Sep 2026

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

Allie Crawley, PhD, Associate Director, Computational Biology

View Insight

// Sep 2026

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Tyler McCullough, Ph.D

View Insight

// Sep 2026

Technology, Not Just Biology, Will Deliver the Future of Medicine

Mike Paglia, Chief Technology Officer

View Insight

// Aug 2026

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

By: Larry Lockwood, Chief Commercial Officer

View Insight

// Sep 2026

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

Allie Crawley, PhD, Associate Director, Computational Biology

View Insight

// Sep 2026

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Tyler McCullough, Ph.D

View Insight

// Sep 2026

Technology, Not Just Biology, Will Deliver the Future of Medicine

Mike Paglia, Chief Technology Officer

View Insight

// Aug 2026

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

By: Larry Lockwood, Chief Commercial Officer

View Insight

// Aug 2026

When Should You Engage a Cell and Gene Therapy CDMO? Earlier Than You Think.

By: Yogesh Waghmare, Senior Director, MSAT

View Insight

// Aug 2026

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

By: ElevateBio

View Insight

// Aug 2026

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

By, Gavin Ellis, Senior Scientist, Translational Biology

View Insight

// Aug 2026

Targeted Gene Insertion Needs More Than One Tool

By: David Wiley, Director, Nucleic Acid Technology

View Insight

// Aug 2026

Can Lipid Nanoparticles (LNPs) Replace Electroporation for T-Cell Engineering?

By: Xiuying Li, Ph.D., Senior Scientist, Technology Development

View Insight

// Jul 2026

Rapid Release Testing Starts With Faster Contaminant Detection

By: Gary Sommerville Ph.D., Principal Scientist, NGS, Technical Services

View Insight

// Jul 2026

The Next Base Editors Will Be Engineered, Not Found

By, Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Jul 2026

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

By, Sean Crosson, Senior Scientist, Translational Biology

View Insight

Capabilities & Services

Expertise

Elevated Insights

Featured Insights

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

When Should You Engage a Cell and Gene Therapy CDMO? Earlier Than You Think.

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

Targeted Gene Insertion Needs More Than One Tool

Can Lipid Nanoparticles (LNPs) Replace Electroporation for T-Cell Engineering?

Rapid Release Testing Starts With Faster Contaminant Detection

The Next Base Editors Will Be Engineered, Not Found

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

Capabilities & Services

Expertise

Elevated Insights

Featured Insights

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?

𝘐𝘯 𝘝𝘪𝘷𝘰 Gene Editing Needs Robust Iteration, Not One-Time Optimization

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

When Should You Engage a Cell and Gene Therapy CDMO? Earlier Than You Think.

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

Targeted Gene Insertion Needs More Than One Tool

Can Lipid Nanoparticles (LNPs) Replace Electroporation for T-Cell Engineering?

Rapid Release Testing Starts With Faster Contaminant Detection

The Next Base Editors Will Be Engineered, Not Found

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

Footer